These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1683452)

  • 1. Toxicity and reconstitution of recombinant interleukin-2 with albumin.
    Miles DW; Longhurst SJ; Harper PG; Balkwill FR
    Lancet; 1991 Dec; 338(8780):1464. PubMed ID: 1683452
    [No Abstract]   [Full Text] [Related]  

  • 2. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.
    Thatcher N; Dazzi H; Johnson RJ; Russell S; Ghosh AK; Moore M; Chadwick G; Craig RD
    Br J Cancer; 1989 Nov; 60(5):770-4. PubMed ID: 2803954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: a phase I/II study.
    Thatcher N; Dazzi H; Gosh A; Johnson RJ
    Cancer Treat Rev; 1989 Jun; 16 Suppl A():49-52. PubMed ID: 2788506
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of interferon-gamma and interleukin-2: tachyphylaxis of toxicity to the liver during increasing immune enhancement.
    Baars JW; Wagstaff J; Van Groeningen CJ; Vermorken JB; Bijvank EM; Pinedo HM; Nauta JJ
    J Natl Cancer Inst; 1993 Mar; 85(5):410-1. PubMed ID: 8433395
    [No Abstract]   [Full Text] [Related]  

  • 6. Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.
    Deehan DJ; Heys SD; Simpson W; Herriot R; Broom J; Eremin O
    Clin Exp Immunol; 1994 Mar; 95(3):366-72. PubMed ID: 7511074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A; Savona S; Gafney E; Penichet KO; Lin BY; Levitt D; Ahmed T; Arlin ZA; Baskind P; Needleman D
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration.
    Caraceni A; Martini C; Belli F; Mascheroni L; Rivoltini L; Arienti F; Cascinelli N
    Eur J Cancer; 1993; 29A(9):1266-9. PubMed ID: 8343265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconstitution of interleukin-2 with albumin for infusion.
    Hamblin T
    Lancet; 1990 Jul; 336(8709):251. PubMed ID: 1973802
    [No Abstract]   [Full Text] [Related]  

  • 10. IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters.
    Dorval T; Mathiot C; Chosidow O; Revuz J; Avril MF; Guillaume JC; Tursz T; Brandely M; Pouillart P; Fridman WH
    Biotechnol Ther; 1992; 3(1-2):63-79. PubMed ID: 1305893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstitution of interleukin 2 with albumin for infusion.
    Miles DW; Bird CR; Wadhwa M; Summerhayes M; Balkwill FR; Thorpe R; Rubens RD
    Lancet; 1990 Jun; 335(8705):1602-3. PubMed ID: 1972528
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
    Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.
    Parkinson DR; Abrams JS; Wiernik PH; Rayner AA; Margolin KA; Van Echo DA; Sznol M; Dutcher JP; Aronson FR; Doroshow JH
    J Clin Oncol; 1990 Oct; 8(10):1650-6. PubMed ID: 2213101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant interleukin-2.
    Bruton JK; Koeller JM
    Pharmacotherapy; 1994; 14(6):635-56. PubMed ID: 7885967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma.
    Bernhardt MB; Hicks MJ; Pappo AS
    Pediatr Blood Cancer; 2009 Dec; 53(7):1346-8. PubMed ID: 19731326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial.
    Thompson JA; Lee DJ; Cox WW; Lindgren CG; Collins C; Neraas KA; Dennin RA; Fefer A
    Cancer Res; 1987 Aug; 47(15):4202-7. PubMed ID: 3496957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keynote address: perspectives on the use of interleukin-2 in cancer treatment.
    Rosenberg SA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S2-6. PubMed ID: 9457385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.